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Leucine-rich repeat kinase 2 (LRRK2) encodes a 
complex protein that includes both kinase and 
GTPase domains. Genome-wide association 
studies have identified dominant LRRK2 alleles 
that predispose their carriers to late-onset 
idiotypic Parkinson’s disease (PD) and also to 
autoimmune disorders such as Crohn’s disease. 
Considerable evidence indicates that PD 
initiation and progression involve the activation 
of innate immune functions in microglia, which 
are brain-resident macrophages. Here, we asked 
whether LRRK2 modifies inflammatory 
signaling and how this modification might 
contribute to PD and Crohn’s disease. We used 
RNA-Seq–based high-resolution transcriptomics 
to compare gene expression in activated primary 
macrophages derived from wild-type and Lrrk2-
knockout mice. Remarkably, expression of a 
single gene, Rap guanine nucleotide exchange 
factor 3 (Rapgef3), was strongly up-regulated in 
the absence of LRRK2 and down-regulated in its 
presence. We observed a similar regulation of 
Rapgef3 expression in cells treated with a highly 
specific inhibitor of LRRK2 protein kinase 
activity. Rapgef3 encodes an exchange protein, 
activated by cAMP 1 (EPAC-1), a guanine 
nucleotide exchange factor that activates the 
small GTPase Rap-1. Rap-1 mediates cell 
adhesion, polarization, and directional motility, 
and our results indicate that LRRK2 modulates 
chemotaxis of microglia and macrophages. 
Dominant PD-associated LRRK2 alleles may 
suppress EPAC-1 activity, further restricting 
motility and preventing efficient migration of 
microglia to sites of neuronal damage. Functional 
analysis in vivo in a sub-clinical infection model 
also indicated that LRRK2 subtly modifies the 
inflammatory response. These results indicate 
that LRRK2 modulates the expression of genes 
involved in murine immune cell chemotaxis. 
 
 
LRRK2 is a large protein of 286 kDa 
consisting of a complex and unique arrangement 
of protein-protein interaction and functional 
domains. This arrangement consists of N-
terminal repeats, including ankyrin repeats, a 
leucine rich repeat (LRR) domain, a Ras of 
complex proteins (Roc) GTPase, with associated 
C-terminal of Roc (COR) domain, a Ser/Thr 
protein kinase, and finally a WD40 domain at the 
C-terminus of the protein(1). The presence of a 
Roc-COR tandem domain defines LRRK2 as a 
member of the Roco protein family, a family first 
detected in the slime mould Dictyostelium 
discoideum (2, 3). 
 There is great interest in all aspects of 
LRRK2 biology because Genome Wide 
Association Studies (GWAS) studies have 
 https://www.jbc.org/cgi/doi/10.1074/jbc.RA119.011842The latest version is at 
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identified many variants in this protein that 
predispose to late-onset Parkinson’s disease. The 
most common mutation in the LRRK2 gene 
results in a change from glycine to serine at amino 
acid 2019 (G2019S). This SNP is the highest 
known risk factor for the development of 
Parkinson’s disease, accounting for 5-7 % of 
autosomal-dominant familial cases (4, 5) and 1-2 
% of sporadic cases in western populations (6). 
GWAS studies have also revealed a link with 
Crohn's disease and leprosy. Genetic links with 
these diseases demonstrate a non-neuronal, but 
clearly innate immune component to LRRK2 
biology (7).  
 LRRK2 expression is enriched in 
macrophages, B-cells and dendritic cells (8). 
Innate immune stimuli such as interferon gamma 
(IFN-γ) stimulate LRRK2 expression, revealing a 
responsiveness to the activation of innate immune 
signalling pathways mediated by pattern 
recognition receptors(9). Furthermore activation 
of Toll-like receptors (TLRs) by pathogen 
associated molecules such as bacterial 
lipopolysaccharide (LPS) leads to 
phosphorylation  of LRRK2 by IkB kinase at two 
serine residues (Ser 910, Ser935) (10). The IkB 
kinase family is normally associated with the 
phosphorylation of IκB proteins that sequester 
NF-κB in the cytoplasm. Phosphorylation and 
ubiquitination of IκB proteins leads to 
proteolysis, and subsequent transfer of NF-κB 
into the nucleus (11). LRRK2 phosphorylation is 
dependent on the TLR adaptor (Myd88), an 
innate immune signal transducer that mediates 
signalling from cell surface TLRs, as well as 
TLR7, 8, and 9 which signal from the endosomal 
compartmen  
The role of inflammatory processes in the 
aetiology of Parkinson’s is further illustrated by 
administration of LPS both systemically and 
directly into the substantia nigra. In the latter case 
LPS causes irreversible degeneration of 
dopaminergic neurons of the pars compacta, 
observed a week after injection (12, 13).  Notably 
non-dopaminergic neurons of the nigrostriatal 
system, as well as proximal dopaminergic 
neurons not associated with the nigrostriatal 
pathway, remain unaffected by direct LPS 
injection. Therefore LPS injection and the 
resulting inflammatory insult demonstrates 
remarkable sensitivity and specificity to the 
dopaminergic circuitry associated with 
Parkinson’s disease.  Another study demonstrated 
that the same pattern of Parkinson’s disease-like 
microglial activation, followed by 
neurodegeneration over ten months was observed 
when LPS or TNFα were administered 
systemically in mice via intraperitoneal injection 
(14). In humans, a laboratory worker accidentally 
exposed to Salmonella derived LPS developed 
many symptoms of Parkinson’s disease including 
bradykinesia, rigidity and tremor at rest, as well 
as other neurological problems resulting from 
damage to the substantia nigra as well as the 
cerebral cortex (15). Human Parkinsonism has 
been further linked to immune activation through 
the role of neurotrophic viral infection, and in 
particular, infection by the human influenza 
virus. Individual cases of viral infection leading 
to neuropathology and death have been reported, 
as well as increased incidence of Parkinson’s 
disease following pandemic flu, such as 
experienced in 1918 (16). 
At present little is known about how 
LRRK2 modifies the gene expression programme 
induced by innate signalling pathways and how 
this might contribute to Parkinson’s disease 
initiation and progression. In this study we have 
used high-resolution transcriptomics to compare 
gene expression in primary macrophages derived 
from wild-type and LRRK2 deficient mice. This 
analysis reveals that LRRK2 modulates the 
expression of a small subset of genes that are 




mRNA sequencing, quality control and read 
mapping 
We have used RNA sequencing to 
determine how LRRK2 modifies gene expression 
in primary bone marrow derived macrophages 
from wild type and LRRK2 -/- mice. If valid 
comparisons are to be made it is necessary to 
confirm the similarity in nature and purity of 
macrophage cultures before RNA extraction and 
RNA sequencing. One day prior to RNA 
extraction, a portion of differentiated 
macrophages were prepared for flow cytometry 
analysis and stained for various cell surface 
markers: CD11b for cells of the myeloid lineage, 
F4/80 for mouse macrophages, and CD11c for 
monocytic-derived cells, including macrophages 















 Role of LRRK2 in inflammation induced chemotaxis 
 3 
differences in the differentiation state of the cells, 
with uniform expression of CD11b, and highly 
similar expression levels of F4/80 and CD11c. 
CD11c surface expression in LRRK2 KO 
macrophages displayed a slightly higher level of 
variability between cultures than WT equivalent 
cells (Fig S1). Overall, cultures were considered 
similar enough to proceed with differential gene 
expression analysis. 
 We then treated WT and LRRK2 -/- 
macrophages with either LPS or muramyl 
dipeptide (MDP), activators of the TLR4 and 
NOD2 mediated innate responses respectively. 
After two hours of stimulation RNA was 
extracted for mRNA sequencing. A mean read 
depth of over 22.2x106 reads/sample was 
achieved with a range of 16.0x106 - 24.9x106 
reads/sample (Table S1). Reads were of high 
quality, requiring a mean of less than 0.1 % of 
reads to be trimmed during quality control. A 
mean of 87.5 % of reads could be unambiguously 
mapped to gene encoding regions of the genome. 
Therefore by comparing the frequency of reads 
per gene between samples, relative levels of 
expression can be determined.  These datasets 
were then analysed for differential gene 
expression. 
 
Differential gene expression 
Datasets of mapped counts were 
interrogated for differences in each LRRK2 
genotype upon innate immune stimulation, as 
well as for underlying differences between 
genotypes in unstimulated cells (Fig 1a). DEseq2 
(18) determines a statistical model accounting for 
variance in counts per gene, and base mean of 
counts allowing the statistical significance of 
apparent differences in gene expression to be 
estimated. This analysis revealed LPS treatment 
caused differential expression of 4985 and 5354 
genes in WT and LRRK2 -/- macrophages 
respectively. By contrast MDP treatment resulted 
in 1483 significantly differentially expressed 
genes in WT macrophages, compared to 1478 
genes in LRRK2 KO macrophages (Fig 1b).   
 In the absence of stimulation only eight 
genes were significantly differentially expressed 
(Table 1). One of these is LRRK2 a result that . is 
confirmed by qPCR. The lesion in the LRRK2 
KO mouse deletes part of exon 1 and exon 2 
leading to termination at an out of frame stop 
codon in exon 3. As the LRRK2 transcription unit 
has 51 exons this should lead to nonsense 
mediated decay (NMD) of the transcript. The 
level of transcript measured is about 50% of the 
wild-type which indicates that NMD is inefficient 
in this case (19) . Other genes regulated include 
Kif21a: a member of the kinesin family of motor 
proteins, Camk2b, a calcium/calmodulin 
responsive protein kinase, Cd59a: a regulator of 
the membrane attack complex in mice, and Nnt: 
a NAD(P) transhydrogenase with implications in 
defence against oxidative stress. Very little is 
known about the Lrmda gene except that it 
consists of a region of LRRs. The remaining 
results are not represented at the protein level and 
so are unlikely to have relevance to the current 
study. The gene detected as being of the highest 
significance, Gm14150, is described as a 
pseudogene, produced by the incorporation of 
reverse transcribed mRNA into the genome, 
while Gm44305 is a retained intron. These are 
likely not differentially expressed genes, but pre-
existing genomic difference between strains (20). 
 The broad characteristics of the MDP and 
LPS responses, as well as similarities and 
differences between WT and LRRK2 deficient 
macrophages in their response to innate immune 
activation were visualised with ‘volcano’ plots 
(Fig. 2). In both LPS and MDP experiments, a 
greater number of genes were up-regulated than 
down-regulated. LPS treatment led to 3192 genes 
being up-regulated and 2696 down-regulated, 
MDP treatment caused 1020 genes to be up-
regulated and 676 down-regulated (Fig 1). 
Furthermore, quantification confirmed that a 
greater number of genes were differentially 
expressed upon LPS treatment in LRRK2 
deficient macrophages than WT macrophages. 
Perhaps the most interesting observation from 
this analysis is that a single gene was found to be 
down-regulated in wild type macrophages and 
up-regulated in LRRK2 -/- macrophages upon 
treatment with LPS. Transcription of this gene, 
Rapgef3, is almost halved upon LPS treatment in 
WT macrophages while being increased just over 
7-fold in LRRK2 null macrophages; a complete 
reversal in transcriptional regulation upon loss of 
LRRK2. 
 
Two parameter analysis identifies a small subset 
of differentially responding genes that are 
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In contrast to conventional differential 
gene expression analysis, two-parameter analysis 
provides an alternative method to identify 
differentially responding genes between 
genotypes (21) (see 
http://bioconductor.org/packages/release/bioc/vi
gnettes/edgeR/inst/doc/edgeRUsersGuide.pdf, 
section3.5). This method revealed eleven genes 
with significantly different responses to LPS as 
between wild type and LRRK2 -/- macrophages 
(Padj <  0.1) (Fig. 3, Table 2). All differentially 
responding genes showed an increased level of 
transcription upon LPS stimulation in LRRK2 
KO cells compared to WT cells. Rapgef3 with a 
Padj  value of 5 x 10-37 and a fold change of about 
11 was the gene most strongly regulated by the 
presence of LRRK2.  Four other genes identified 
encode either chemokine ligands (Ccl3, 4 , 5) or 
receptors (Ccrl2) that mediate chemotactic 
responses, suggesting a common theme of 
regulated motility (see Discussion).  
In order to confirm the results of the 
RNASeq experiments qRT-PCR was used to 
directly measure the level of 6 of the 11 genes 
identified in WT and LRRK2 -/- macrophages 
(Fig. 4A). This confirms the results of the 
RNASeq analysis for Rapgef3, chemokines and 
transcription factor Atf-3. We next asked whether 
chemical inhibition of the LRRK2 kinase also 
induces the expression of Rapgef3. We treated 
wild-type and LRRK2 -/- macrophages with the 
highly specific inhibitor GSK2578215A (22). 
Rapgef3 was induced about 6 fold in treated, 
wildtype macrophages as compared to untreated 
controls. By contrast no differences in expression 
level were detected when LRRK2 mutant 
macrophages were treated with GSK2578215A 
relative to the untreated controls (Fig. 4B). Thus, 
LRRK2 kinase activity is required for the 
observed regulation of Rapgef3 gene expression, 
consistent with the results of the RNASeq 
analysis. 
In contrast to LPS, MDP treatment 
identified no significant differentially responding 
genes (Fig. 3c,d). This aligns with the less 
immunogenic nature of MDP compared to LPS 
stimulation and demonstrates the high stringency 
of the two-parameter method.  
 
Elevated levels of EPAC-1 protein in activated 
macrophages lacking LRRK2.  
To determine whether of Rapgef3 mRNA 
and EPAC-1 protein levels are correlated we 
stained LRRK2 deficient and wildtype 
macrophages with a fluorescent monoclonal 
antibody specific for EPAC-1. As shown in Fig. 
5a EPAC-1 is ubiquitous and in many cells is 
distributed in the expected punctate, peri-nuclear 
pattern (Fig. S2). We then quantified protein 
levels and 6 hours after treatment with LPS the 
LRRK2 deficient cells have significantly higher 
levels of EPAC-1, consistent with the RNASeq 
and qPCR results (Fig. 5b). We were unable 
further validate these observations using western 
blot as the available antibodies are insufficiently 
specific or sensitive in this assay.  
 
A sustained inflammatory response in LRRK2 
knock out mice. 
 To explore whether LRRK2 affects 
innate immune function we have used a model of 
sub-clinical bacterial infection. Wild type and 
LRRK2 deficient mice were infected with 
Salmonella typhimurium and three markers of 
inflammation, interleukin 18 (IL-18), interferon 
g  (IFNg) and splenomegaly were measured. As 
shown in Fig. 6 LRRK2 -/- mice have elevated 
levels of both IL-18 and IFNg compared to 
controls at 14 days post challenge. These results 
are statistically significant (p< 0.05, with the 
exception IFNg at 14 days p=0.06; see legend to 
Fig 6). This indicates that the absence of LRRK2 
causes an enhanced inflammatory response.  
 
Discussion 
In this study we investigated how LRRK2 
modifies inflammatory signalling mediated by 
LPS and MDP. We have identified a small subset 
of genes that are activated by LPS in 
macrophages that lack LRRK2 but not in wild-
type control cells. About half of these molecules 
are involved in cell migration, motility and 
chemotaxis. Of particular note is the guanine 
nucleotide exchange factor (GEF) Rapgef3, by 
far the most strongly induced gene identified with 
an 11-15 fold increase in transcription in the 
absence of LRRK2. Rapgef3 is also the only gene 
that is down regulated in wild type macrophages 
but up regulated in LRRK2 -/- cells, as compared 
to unstimulated control cells. Rapgef 3 is also 
derepressed by treatment of macrophages with 















 Role of LRRK2 in inflammation induced chemotaxis 
 5 
GSK2578215A (22), indicating that inter- or 
intra- molecular phosphorylation is required. 
 Rapgef3 encodes EPAC-1 a GEF that 
mediates cAMP dependent activation of the small 
G-protein Rap1. EPAC promotes Rap-1 GDP-
GTP exchange leading to cell adhesion, cell 
polarization and enhanced leucocyte chemotaxis 
(23, 24). On the other hand another study found 
that LPS treatment paralyzes monocyte 
chemotaxis, an effect that requires activated Rap-
1 (25).  It is thus likely that LRRK2 indirectly 
regulates the mobility of macrophages and 
microglia that have been activated by innate 
stimuli such as LPS. An attractive hypothesis is 
that dominant PD associated LRRK2 alleles such 
as G2019S that have higher constitutive kinase 
activity may regulate the motility of macrophages 
by further suppressing EPAC-1 levels. In that 
regard a recent study found that G2019S 
microglia and LRRK2 -/- cells when activated by 
ADP have retarded and enhanced motility 
respectively as compared to wild-type control 
cells. G2019S microglia also have an impaired 
ability to isolate brain injury (26). These authors 
present evidence for the involvement of focal 
adhesion kinases, however this may be indirect 
and a possible role of the LRRK2/EPAC-1/Rap1 
axis should be investigated. 
 LRRK2 is part of an ancient and highly 
conserved pathway of directional motility (2). In 
the slime mould Dictyostelium gbpC is one of 
eleven paralogues of LRRK2. GbpC null cells are 
severely defective in chemotaxis because they 
cannot polarize cells effectively and have altered 
patterns of myosin phosphorylation that are 
probably mediated by activation of Rap1. It is 
interesting to note also that in Dictyostelium 
many LRRK2 paralogues encode GEFs within 
their modular structure. 
 As well as EPAC1 four other messages 
that function in chemotaxis are differentially 
expressed. Three are chemokines, and one is a 
chemokine receptor-like protein. CCL3 and 
CCL4 are also known as ‘macrophage 
inflammatory protein 1’; MIP-1α and MIP-1β 
respectively. CCL5 is also known as ‘regulated 
on activation, normal T cell expressed and 
secreted’ (RANTES). These chemokines are all 
members of the ‘CC Chemokine/Receptor 
family’ and share a common receptor in CCR5. 
CCL3 and CCL5 may also bind CCR1, while 
CCL5 binds a further receptor, CCR3(27). These 
chemokines are all classified as pro-
inflammatory, meaning they are induced by 
inflammatory stimuli to recruit inflammatory 
cells to a site of inflammation, as opposed to 
homeostatic chemokines, which are 
constitutively expressed in certain tissues (28). 
CCRL2 is chemokine receptor-like protein, with 
over 40 % sequence identity to CCR1, CCR2, 
CCR3 and CCR5 (29) and highest amino acid 
sequence similarity to CCR1. Interestingly, 
CCRL2 has been reported as a non-canonical 
receptor for CCL5 (30), as well as CCL19 and 
chemerin (31). A microarray screen of 
unstimulated mouse microglia has shown that 
CX3CR1, a non-canonical chemokine receptor of 
fractalkine, expressed exclusively in microglia, is 
upregulated by knockout of LRRK2 (32). This 
reaffirms that chemokine responses may be 
involved in LRRK2 biology in diverse 
immunological contexts.  
Message encoding the transcription 
factor ATF3 is induced by 3 fold in the absence 
of LRRK2 and is a negative regulator of pro-
inflammatory TLR4 signalling, a part of the LPS 
induced negative-feedback loop (33, 34). Thus it 
is possible that G2019S mutation of LRRK2 
might down regulate ATF3, resulting in 
attenuated negative feedback of TLR4 signalling, 
enhanced inflammation, and greater neuronal 
stress. Other transcription factors messages 
identified encode MXD1 and CSRNP1. MXD1 
acts in a network with MYC and MAX, forming 
the MYC/MAX/MXD1 axis (33). MXD1 is in 
competition with MYC for the binding of MAX 
leading to a mixture of MXD1/MAX and 
MYC/MAX dimers controlling transcriptional 
output. In the context of cancer, MYC signalling 
affects cell adhesion, cell shape, and reduces cell 
migration through modulation of the actin 
cytoskeleton (35). Finally, CSRNP1 is a 
transcription factor that is upregulated by Axin, 
as well as inflammatory stimuli in the form of IL-
2 (36, 37). Axin is a negative regulator of the Wnt 
signalling pathway, acting to sequester the 
transcription factor β-catenin to the cytoplasm 
(38).  
Two transcripts identified have been 
linked directly to Parkinson’s disease. Abtb2 
encodes ‘Ankyrin-rich BTB/POZ domain 
containing protein-2’ (BPOZ-2). This protein 
causes inhibition of alpha-synuclein aggregation 
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appears to stimulate autophagic clearance of 
alpha-synuclein, resulting in reduced alpha-
synuclein pathology in the basal ganglia. Another 
protein identified is the G protein-coupled 
receptor, HCAR2, otherwise known as ‘niacin 
receptor 1’. Niacin has been proposed as a 
treatment for Parkinson’s disease, although 
evidence of efficacy is lacking (40, 41). 
Activation of HCAR2 in macrophages has an 
anti-inflammatory effect. Activation by niacin 
results in inhibition of CCL2 induced 
macrophage migration (42), as well as an 
inhibited response to LPS stimulation (43) or 
inflammatory cytokine release (44). 
Previous studies of LRRK2 using kinase 
inhibitors have revealed immunological 
functions. However these results should be 
treated with caution owing to significant off-
target effects that act on the ERK pathway (45). 
We therefore used a sub-clinical infection model 
to test for inflammatory phenotypes in the 
LRRK2 -/- mice. Mice were infected with 
Salmonella typhimurium and this revealed that 
LRRK2 significantly dampens the inflammatory  
response. In this model IL-18 comes most likely 
from myeloid cells, particularly monocytes and 
the principal inflammatory activator of 
Salmonella is LPS. This suggests that the 
observed differences in gene expression reported 
here cause subtle but significant changes in the 
inflammatory response in vivo that may be 
caused by alterations in the chemotactic capacity 
of monocytes and macrophages 
 It is interesting that only a small number 
of differentially expressed genes were observed 
between LRRK2 genotypes under resting 
conditions. This shows that LRRK2 only exerts 
an effect on the macrophage transcriptome under 
stimulated conditions. This finding also reflects 
work by another group that identified no changes 
in gene expression in unstimulated human 
fibroblasts or brain tissue between G2019S 
LRRK2 carriers and controls (46).  
 In conclusion the current study identifies 
the control of directional motility and chemotaxis 
of macrophages by LRRK2 as a potentially 
critical mechanism in the aetiology of PD. It 
suggests that the function and regulation of the 
LRRK2/EPAC-1/Rap1 axis and how this impacts 
on pro- and anti-inflammatory properties of 
microglia should be investigated. If active EPAC-
1/Rap1 confers a neuroprotective phenotype on 
microglia, EPAC-1 specific agonists such as 
cAMP analog, 8-(4-chloro-phenylthio)-2′-O-
methyladenosine-3′,5′-cyclic monophosphate (8-
pCPT-2′-O-MecAMP) may have therapeutic 
value in PD (47). 
 
Experimental procedures 
Mice, genotyping and cell culture 
WT C57BL/6J mice were obtained from Charles 
River, UK. LRRK2-/- B6.129X1(FVB)-
Lrrk2tm1.1Cai/J mice were obtained from The 
Jackson Laboratory, United States (48). All mice 
strains were bred independently. All work 
involving live animals complied with the 
University of Cambridge Ethics Committee 
regulations and was performed under the Home 
Office Project License number 80/2572. DNA 
from Ear snips of LRRK2-/- B6.129X1(FVB)-
Lrrk2tm1.1Cai/J mice was isolated for genotyping 
using the Phire animal tissue digest PCR kit 
(Thermo Fisher Scientific, USA). Genotyping 
PCR was carried out in accordance with 
recommendations by the Jackson Laboratory.. 
Genotyping PCR products were run on a 1 % 
agarose gel.  
For the differentiation and culture of 
‘primary bone marrow derived macrophages’ 
(pBMDMs), mice were killed between 8 and 16 
weeks of age by cervical dislocation, skin was 
sterilized with 70 % ethanol, and legs removed. 
Under sterile conditions, the tibia and femur were 
isolated, cleaned of muscle, and the proximal and 
distal epiphysis cut away. Bone marrow was 
flushed out of the bone using primary growth 
media (Dulbecco's modified Eagle's medium 
(DMEM) (Thermo Fisher Scientific, USA) 
supplemented with 10 % foetal calf serum’ (FCS) 
(Thermo Fisher Scientific, USA), 20 % L929 
conditioned media and 8 mM L-glutamine 
(Sigma-Aldrich, USA)). Isolated cells were 
centrifuged at 300 g for 10 min at 15 °C, and re-
suspended in 60 ml of growth media, and allowed 
to grow at 37 °C in 5 % CO2. Cells were 
supplemented with a further 60 ml of growth 
media after 2 days, and media replaced every 3 
days. All experiments were performed on cells 
between 6 and 11 days after initial bone marrow 
isolation. Live cell counts were performed using 
a haemocytometer with trypan blue staining 
















 Role of LRRK2 in inflammation induced chemotaxis 
 7 
Animal Infections and Data Collection 
S. Typhimurium strain M525P (49) a strain of 
intermediate virulence, was used to establish a 
subclinical infection in vivo. In particular, 
overnight (stationary phase) bacterial cultures 
were first washed and resuspended in Dulbecco’s 
PBS (D-PBS, Sigma) and then diluted to the 
desired dose. Wild-type and Lrrk2-/- mice were 
subsequently challenged intravenously 
with  0.2ml of the bacterial suspension. The exact 
dose, as determined by serial dilution and plating 
the inoculum on LB plates before and after 
infection, was 1.3x104 CFU/mouse. Mice were 
bled and then euthanised at certain intervals after 
the initial challenge, their spleens were 
aseptically removed and weighed. Mouse serum 
was analysed via ELISA for levels of  IL-18 
(MBL International) and IFN-g (DuoSet 
Development kit, R&D Systems). 
 
Flow cytometry 
1x106 cells/well were plated in 12-well tissue 
culture plates and left to adhere over night at 37 
°C in 5 % CO2. Cells were then resuspended into 
MACS buffer (PBS supplemented with 2 % FCS, 
1 mM EDTA (Merck and Co, USA)) and spun at 
300 g for 6 minutes in a conical-bottom 96-well 
plate (Thermo Fisher Scientific, USA). To block 
Fc-mediated reactions, cells were re-suspended in 
MACS buffer supplemented with 1:100 rat anti-
mouse CD16/CD32 functional grade purified (93 
clone; eBioscience, USA) and incubated at 4 °C 
for 15 minutes. Cells were spun at 300 g for 6 
minutes, then re-suspended in MACS buffer 
supplemented with rat anti-F4/80 conjugated 
with FITC, hamster anti-CD11c conjugated with 
phycoerythrin and rat anti-CD11b conjugated 
with PerCP-cyanine5.5. Staining was performed 
for 30 mins at 4 °C. Cells were then centrifuged 
at 300 g for 6 mins and re-suspended in MACS 
buffer 3 x to remove unbound antibody before 
finally being spun at 300 g for 6 minutes, and re-
suspended in MACS buffer supplemented with 2 
% methanol-free formaldehyde (Thermo Fisher 
Scientific, USA) to fix. Fixed cells were analysed 
using an Attune NxT acoustic focusing cytometer 
(Life Technologies, USA) for triple labeling 
experiments. 
 
RNA sequencing and transcriptomic data 
analysis 
Bone marrow was isolated from 16-week old 
female mice housed in the same facility for this 
study. 3x106 cells/well were plated in Greiner 6-
well tissue culture plates (Sigma-Aldrich, USA) 
a day prior to RNA extraction and left to adhere 
over night at 37 °C in 5 % CO2. Where 
appropriate, cells were then treated with 100 
ng/ml ultrapure LPS from E. coli O111:B4, or 10 
µg/ml MDP. LPS was sonicated prior to 
application to cells. After 2 hours incubation at 37 
°C in 5 % CO2, cells were washed in PBS, then 
scraped into PBS at 4 °C. RNA was isolated using 
RNeasy mini kit in combination with 
QIAshredder cell homogenization following the 
manufacturers instructions. To remove genomic 
DNA, extracted RNA was DNase treated using 
TURBO DNA-free kit. Resulting RNA was 
analysed using a Nanodrop 1000 
spectrophotometer. Samples with A260/230 < 1.8 
were further purified with RNeasy MinElute 
Cleanup Kit (Qiagen, Germany). Samples were 
then flash frozen in liquid nitrogen, and RNA was 
quantified using a Qubit Fluorometer (Thermo 
Fisher Scientific, USA). RNA integrity was 
verified using 2100 Bioanlyser (Agilent 
Genomics, USA), and mRNA library preparation 
was performed using TruSeq Stranded mRNA 
Library Prep Kit (Illumina, USA) with quality 
control by 2200 Tapestation (Agilent Genomics, 
USA). High output sequencing runs of single-end 
75 bp read length were performed on NextSeq500 
(Illumina, USA) using NextSeq 500/550 High 
Output v2 Kit (75 cycles) (Illumina, USA). A 
minimum read depth of 18x106 reads per sample 
was achieved. Read pre-processing, mapping 
with quality control was performed using a 
standard pipeline. Ensembl 
Mus_musculus.GRCm38.dna.primary_assembly
.fa (release 84) reference genome file was used to 
map reads, using the annotated transcripts from 
the ensembl Mus_musculus.GRCm38.84.gtf. 
Differential gene expression analysis was 
performed using DESeq2. Analysis was 
performed as a ‘paired comparison experiment’ 
for each treatment group as comparisons between 
genotype are made between different samples of 
different mice (unpaired), while comparisons of 
treated vs untreated samples are made using 
samples from the same mice (paired). A target 
frame and design matrix were adapted from an 
analogous scenario laid out in the EdgeR user 
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and within subjects” (21). This analysis enabled 
simple differential gene expression analysis 
between genotypes, and 2-parameter analysis to 
compare responses of each genotype to innate 
immune stimuli by interrogation of a targets 
frame. This targets frame identifies each sample 
as belonging to a mouse (mouse.n), and each of 
these mice as being treated with LPS, MDP, or 
left untreated (media). 
 
Quantitative reverse transcription PCR 
qRT-PCR was performed using SensiFAST 
SYBR No-ROX One-Step Kit (Bioline, UK) 
following the manufacturers instructions and 
appropriate primers selected based on data 
submitted to the primer bank database (table 
4)(50). qRT-PCR reactions were performed using 
a Rotor-Gene Q (Qiagen, Germany), and 
quantification of fold-changes of transcript were 
calculated using cycle threshold values 
accounting for reaction efficiency (51). For 
inhibitor studies, cells were pre-treated with 1.3 
µM of GSK2578215A for four hours. Following 
this, they were treated with 100 ng/ml of LPS for 
a further two hours. Cells were then washed with 
1X PBS and harvested. Total RNA was used for 
RT-qPCR using the Luna One step RT-qPCR kit 




Cells were fixed with 4% paraformaldehyde and 
permeabilized with 0.1% Triton X100 (20min), 
and then blocked by washing with 0.05% Tween 
20 in PBS, followed by blocking for 30min at 
37ºC in 0.05% Tween 20 0.5% BSA. Cells were 
immune-stained overnight at 4ºC with Alexa-488 
conjugated Anti-EPAC1 monoclonal antibody 
(Abcam ab201506). The Anti-Epac1 antibody is 
raised against human-EPAC but to an epitope that 
is conserved in the mouse homologue. After 
staining, slides were washed with blocking 
buffer, PBS, and then mounted in curing 
mountant with DAPI (Diamond antifade, Thermo 
Fisher P36966). 
Fluorescence was detected under a 
FV1200 confocal microscope 60x oil immersion 
objective with integration as 512x512 pixels each 
0.413x0.413µm with detector gain set for 
minimal saturated pixel count (4096 in the 13bit 
intensity Olympus format). Z-stacks of 5x1µm 
depth were collected upwards from the coverslip 
to collect the total cellular fluorescence. 
Projections summing each pixel in each z series 
were calculated in ImageJ and the image 
converted to ‘FITS’ image format to preserve the 
Olympus raw pixel intensity count data. Fields of 
view from media-treated and LPS-treated cells 
for each genotype were collected in batches of 10 
images as close in time as possible. As a result 
intensity differences within a genotype are more 
reliable than comparison between genotypes. 
This approach was chosen so that the differing 
response of the cell types to LPS could be 
detected more accurately. 
Projection image analysis was with 
Mathematica 11 – cell bodies were masked using 
the MorphologicalBinarize function extended by  
a border of 5 pixels (2µm) for edge inclusion. Cell 
number was obtained from the binarized DAPI 
channel using the MorphologicalComponent 
function to give a count of the nuclei. EPAC1 
immuno-fluorescence from both cytoplasm and 
nuclei compartments were summed typically 
giving an intensity of millions of Olympus 
fluorescence units. Data from approximately 200-
300 cells in 20 fields of view were analysed for 
each sample and reported mean intensity given in 
million units per cell. Cells cut by image borders 
were included in the pixel counts even if not 
containing the nucleus (as on average a cell 
should be cut by a border into two halves one with 
and one without a nucleus). The mean total 
intensity per cell was calculated as a measure of 
EPAC1 expression with a S.E.M. based on 
number of fields of view included (rather than the 
number of cells).  Ratios of average fluorescence 
per cell in LPS treated vs medium were calculated 
at each time point for each genotype. In addition, 
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Table 1: Differentially expressed genes between unstimulated macrophages. Genes with padj 
< 0.01. LRRK2 KO/WT pBMDM cells. Genes not represented at the protein level are displayed 
in grey.  
 
  
Ensembl gene ID baseMean 
Fold change 
(KO/WT) 
Padj Gene Symbol 
ENSMUSG00000082809 177.98 5.65 2.52E-92 Pseudogene Gm14150 
ENSMUSG00000063458 83.02 0.44 3.99E-20 Lrmda 
ENSMUSG00000022629 31.47 1.93 1.07E-14 Kif21a 
ENSMUSG00000105703 89.25 2.01 1.94E-13 Gm43305 
ENSMUSG00000036273 137.37 0.54 8.10E-10 Lrrk2 
ENSMUSG00000057897 58.28 1.66 1.17E-07 Camk2b 
ENSMUSG00000032679 297.27 1.55 1.02E-04 Cd59a 



















Table 2: Differentially responding genes in LPS stimulated macrophages. Genes with padj < 





Ensembl gene ID baseMean Fold change (KO/WT) Padj Gene Symbol 
ENSMUSG00000022469 176.34 10.97 4.98E-37 Rapgef3 
ENSMUSG00000018930 11796.25 3.26 1.94E-12 Ccl4 
ENSMUSG00000026628 2039.03 2.72 5.58E-07 Atf3 
ENSMUSG00000000982 4095.93 2.24 1.02E-03 Ccl3 
ENSMUSG00000032515 1117.61 1.73 1.07E-03 Csrnp1 
ENSMUSG00000032724 417.68 2.80 5.72E-03 Abtb2 
ENSMUSG00000035042 3664.77 2.02 2.75E-02 Ccl5 
ENSMUSG00000043953 1652.79 3.39 2.75E-02 Ccrl2 
ENSMUSG00000045502 249.85 3.55 4.19E-02 Hcar2 
ENSMUSG00000001156 477.83 2.09 9.07E-02 Mxd1 
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1             2             3 
Figure 1: Differential gene expression analysis. a: LRRK2 genotype (red), and treatment with 
innate immune stimuli (blue), are considered separately in these experiments. b: Quantification of 
differentially expressed genes. KO refers to the LRRK2 KO genotype. Numbers refer to 





































Figure 2: ‘Volcano plot’ visualisation of transcriptional gene responses. Dots represent 
individual genes. Red indicates padj < 0.01. a,c: WT pBMDM cells. b,d: LRRK2 KO pBMDM 
cells.  
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LRRK2 WT vs KO: 100 ng/ml LPS
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LRRK2 WT vs KO: 10 ug/ml MDP
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Figure 3:  Visualisation of differentially responding genes.  Fold changes are ligand treated gene expression levels (LRRK2 KO/WT). 












































Figure 4: Transcript levels upon LPS stimulation. (A) qRT-PCR with beta-actin and GAPDH 
as housekeeping genes. Each point is a different LRRK2 KO pBMDM sample compared to three 
different WT pBMDM samples. Error bars are S.E.M. Paired two-tailed t tests compared to a 
value of 1. (B) Equal aliquots of wild type (blue bars) and LRRK2 -/- (orange bars) macrophages 
were incubated for 4 hours with or without the GSK2578215A inhibitor (1.3µM) and then 
stimulated with LPS for 2 hours. Rapgef3 RNA was then quantified by qRT-PCR. Wild type, 
untreated cells have active LRRK2 and therefore Rapgef3 expression is relatively inhibited as 
compared to the equivalent treated cells whereas mutant macrophages have similar levels of 





















































































Figure 5. Elevated levels of EPAC-1 in activated macrophages lacking LRRK2. 
(a) Immunofluorescent images of cells stained with Alexa-488 conjugated Anti-EPAC1 
monoclonal antibody (green) and DAPI (blue). 
(b) Projection image analysis of untreated and LPS stimulated macrophages. The ratios of 
average fluorescence per cell in LPS treated vs medium were calculated at each time point for 



















Figure 6.  LRRK2 dampens inflammation in a subclinical infection model. 
Wildtype and LRRK2 -/-  (n=5) mice were infected with Salmonella typhimurium 525P. IL-18 
(a), interferon g (b) and spleen weight (c) were measured. Significance was evaluated with the 
Man-Whitney test. Differences in IL-18 were significant (day1: P=0.0159 (*), day 14: P=0.0159 
(*) day 35: P=0.0095 (**)), IFNg although elevated at day 14 was not significant at the 95% 
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